Added to YB: 2025-05-14
Pitch date: 2025-05-09
NVO [neutral]
Novo Nordisk A/S
-22.27%
current return
Author Info
Kontra Investment Xchange is trying to build wealth by investing in good companies and letting those investments compound over many years. Sign up for the newsletter.
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally.
Market Cap
DKK 1.4T
Pitch Price
DKK 413.17
Price Target
N/A
Dividend
3.64%
EV/EBITDA
8.92
P/E
13.70
EV/Sales
4.72
Sector
Pharmaceuticals
Category
growth
Novo Nordisk ($NVO): Robust momentum despite US market challenges – Q1´25 update
NVO (earnings update): Strong Q1 with 19% sales growth to DKK 78.1B, 22% op profit growth to DKK 38.8B. Obesity care +65%, but US Wegovy facing compounded GLP-1 headwinds. Catalysts: CVS preferred status July 2025, 25 int'l markets, oral semaglutide, CagriSema filing 2026. Est $50 EPS by 2029. Dominant 2/3 GLP-1 mkt share.
Read full article (6 min)